13346 Federal Register / Vol. 77, No. 44 / Tuesday, March 6, 2012 / Notices 

identified in the research represent both 

promising means for diagnosing SS 

earlier in disease progression as well as 

therapeutic targets to treat SS. 

Potential Commercial Applications: 

• Diagnosis of Sjo ̈gren’s syndrome 

• Treatment of Sjo ̈gren’s syndrome 

Competitive Advantages: The genes 

and autoantibodies identified in this 

technology may lead to one of the first 

diagnostic tests for Sjo ̈gren’s syndrome. 

Development Stage: 

• Early-stage 

• In vitro data available 

Inventors: Sharon M. Wahl (NIDCR), 

et al. 

Publications: 

1. Greenwell-Wild T, et al. Chitinases in 

the salivary glands and circulation of patients 

with Sjo ̈gren’s syndrome: macrophage 

harbingers of disease severity. Arthritis 

Rheum. 2011 Oct;63(10):3103–3115, doi: 

10.1002/art.30465. [PMID 21618203] 

2. Katsifis GE, et al. Systemic and local 

interleukin-17 and linked cytokines 

associated with Sjo ̈gren’s syndrome 

immunopathogenesis. Am J Pathol. 2009 

Sep;175(3):1167–1177. [PMID 19700754] 

3. Moutsopoulos NM, et al. Lack of efficacy 

of etanercept in Sjo ̈gren syndrome correlates 

with failed suppression of tumour necrosis 

factor alpha and systemic immune activation. 

Ann Rheum Dis. 2008 Oct;67(10):1437–1443. 

[PMID 18198195] 

4. Mavragani CP, et al. Augmented 

interferon-alpha pathway activation in 

patients with Sjo ̈gren’s syndrome treated 

with etanercept. Arthritis Rheum. 2007 

Dec;56(12):3995–4004. [PMID 18050196] 

5. Katsifis GE, et al. T lymphocytes in 

Sjo ̈gren’s syndrome: contributors to and 

regulators of pathophysiology. Clin Rev 

Allergy Immunol. 2007 Jun;32(3):252–264. 

[PMID 17992592] 

Intellectual Property: 

• HHS Reference No. E–140–2011/0 

— U.S. Provisional Application No. 61/ 

476,192 filed 15 April 2011 

• HHS Reference No. E–140–2011/1 

— U.S. Provisional Application No. 61/ 

556,729 filed 07 November 2011 

Licensing Contact: Jaime M. Greene, 

M.S.; 301–435–5559; 

greenejaime@mail.nih.gov. 

Bacterially Expressed Influenza Virus 

Recombinant HA Proteins for Vaccine 

and Diagnostic Applications 

Description of Technology: Pandemic 

H1N1 influenza virus is a recently 

emergent strain of influenza virus that 

the World Health Organization (WHO) 

estimates has killed at least 14,711 

people worldwide. Avian influenza 

viruses are emerging health threats with 

pandemic potential. Due to their global 

health implications, there has been a 

massive international effort to produce 

protective vaccines against these 

influenza virus strains. Currently, 

influenza virus vaccines are produced 

in chicken eggs, a production method 

that is disadvantaged by lengthy vaccine 

production times and by inability to 

meet large-scale, global demands. 

The subject technologies are specific 

recombinant HA proteins from H1N1, 

H5N1, and other strains of influenza 

virus produced in bacteria. The HA 

proteins properly fold, form oligomers, 

bind fetuin, agglutinate red blood cells 

and induce strong neutralizing antibody 

titers in several in vivo animal models. 

The key advantages of this technology 

are that expression of these proteins in 

bacteria reduces the vaccine production 

time and offers the ease of scalability for 

global usage, an issue with current 

production methods. The recombinant 

HA proteins can also be used for 

diagnostic applications. 

Potential Commercial Applications: 

• Vaccines for the prevention of 

influenza infection 

• Diagnostics for influenza virus 

specific antibodies 

Competitive Advantages: 

• Novel vaccine candidates 

• Rapid production time 

• Ease of scalability 

Development Stage: 

• In vitro data available 

• In vivo data available (animal) 

Inventors: Hana Golding and Surender 

Khurana (FDA). 

Publication: Khurana S, et al. 

Recombinant HA1 produced in E. coli 

forms functional oligomers and 

generates strain-specific SRID potency 

antibodies for pandemic influenza 

vaccines. Vaccine. 2011 Aug 

5;29(34):5657–5665. [PMID 21704111]. 

Intellectual Property: HHS Reference 

No. E–032–2010/1—PCT Application 

No. PCT/US2010/055166 filed 02 Nov 

2010. 

Licensing Contact: Kevin W. Chang, 

Ph.D.; 301–435–5018; 

changke@mail.nih.gov. 

Potent, Easy To Use Targeted Toxins as 

Anti-Tumor Agents 

Description of Technology: The 

invention discloses synthesis and use of 

novel derivatives of 2-[2’-(2- 

aminoethyl)-2-methyl-ethyl]-l,2- 

dihydro-6-methoxy-3H-dibenz- 

[de,h]isoquinoline-l,3-dione as targeted 

anti-tumor agents. The use of targeted 

toxin conjugates with anti-cancer 

antibodies, such as herceptin, is 

increasing. Based on a comparison with 

the structurally complex toxins, such as 

DM1, available in the market, these 

novel toxins are more stable in 

circulation, thus making the toxinconjugates more tumor-selective and 

less toxic. As such, these compounds 

are superior alternatives to the existing 

toxins. 

The invention describes a potent and 

easy to synthesize toxin that can be used 

for generating a variety of prodrugs. 

These compounds can be attached to a 

ligand that recognizes a receptor on 

cancer cells, or to a peptide that is 

cleaved by tumor-specific proteases. 

The compounds are topoisomerase 

inhibitors and are mechanistically 

different from DM1 that targets tubulin. 

The structure of the toxin allows it to 

be modified with a peptide linker that 

is stable, but rapidly cleaved in 

lysosomes after the compound is 

specifically taken up by cancer cells. 

Potential Commercial Applications: 

The compounds can be used for 

preparation of a variety of potent anticancer agents with low systemic 

toxicity. 

Competitive Advantages: 

• Easy to prepare 

• Structural features make these 

compounds more stable in circulation 

• Toxin conjugates are more tumorselective and less toxic 

Development Status: 

• In vitro data available 

• In vivo data available (animal) 

Inventors: Nadya Tarasova, et al. 

(NCI). 

Intellectual Property: HHS Reference 

No. E–160–2006/0—U.S. Patent No. 

8,008,316 issued 30 Aug 2011. 

Licensing Contact: Jennifer Wong; 

301–465–4633; wongje@mail.nih.gov. 

Dated: February 29, 2012. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2012–5356 Filed 3–5–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 


pmangrum on DSK3VPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 44 / Tuesday, March 6, 2012 / Notices 13347 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Epidemiology and Genetics of 

Chronic Disease. 

Date: March 28–29, 2012. 

Time: 10 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Julia Krushkal, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3148, 

MSC 7770, Bethesda, MD 20892, 301–435– 

1782, krushkalj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Epidermal, 

Lupus, and Wound Healing. 

Date: March 28–29, 2012. 

Time: 10 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Baljit S Moonga, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4214, 

MSC 7806, Bethesda, MD 20892, 301–435– 

1777, moongabs@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 29, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–5419 Filed 3–5–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Biomedical 

Imaging and Bioengineering; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Biomedical Imaging and Bioengineering 

Special Emphasis Panel; Career Awards 

(2012/05). 

Date: March 26, 2012. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Ruixia Zhou, Ph.D., 

Scientific Review Officer, 6707 Democracy 

Boulevard, Democracy Two Building, Suite 

957, Bethesda, MD 20892, 301–496–4773, 

zhour@mail.nih.gov. 

Name of Committee: National Institute of 

Biomedical Imaging and Bioengineering 

Special Emphasis Panel; Point-of-Care 

Technologies Research Network (U54). 

Date: March 28–29, 2012. 

Time: 6 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: John K. Hayes, Ph.D., 

Scientific Review Officer, 6707 Democracy 

Boulevard, Room 959, Bethesda, MD 20892, 

301–451–3398, hayesj@mail.nih.gov. 

Dated: February 29, 2012. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–5425 Filed 3–5–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Ruth L. Kirschstein National 

Research Service Award (NRSA) Institutional 

Research Training Grants (Parent T32). 

Date: March 30, 2012. 

Time: 9:30 a.m. to 12:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817, 

(Telephone Conference Call). 

Contact Person: Sujata Vijh, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

NIAID/NIH/DHHS, 6700B Rockledge Drive, 

MSC 7616, Bethesda, MD 20892–7616, 301– 

594–0985, vijhs@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: February 29, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–5423 Filed 3–5–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the Board 

of Scientific Counselors, NIDCD. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Institute on Deafness and 

Other Communication Disorders, 

including consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of 

Scientific Counselors, NIDCD. 

Date: March 22, 2012. 

Time: 1 p.m. to 2 p.m. 

Agenda: To review and evaluate 

personal qualifications and 

performance, and competence of 

individual investigators. 

Place: National Institutes of Health, 5 

Research Court, Rockville, MD 20852 

(Telephone Conference Call). 

Contact Person: Andrew J. Griffith, 

Ph.D., MD, Director, Division of 

Intramural Research, National Institute 

on Deafness and Other Communication 

Disorders, 5 Research Court, Room 


pmangrum on DSK3VPTVN1PROD with NOTICES